REG - AstraZeneca PLC - AstraZeneca completes divestment of Imdur <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

03/05/2016 07:13

RNS Number : 9466W
AstraZeneca PLC
03 May 2016
ASTRAZENECA COMPLETES DIVESTMENT OF IMDUR 
TO CHINA MEDICAL SYSTEM HOLDINGS
AstraZeneca today announced that it has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $190 million for the rights to Imdur.
Imdur is a mature medicine for the prevention of angina in patients with heart disease and achieved global sales outside the US of $57 million in 2015. Income from the agreement will be reported as Core Other Operating Income.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries

Neil Burrows
UK/Global
+44 20 7604 8032
Vanessa Rhodes
UK/Global
+44 20 7604 8037
Karen Birmingham
UK/Global
+44 20 7604 8120
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Enquiries


UK


Thomas Kudsk Larsen

+44 7818 524185
Eugenia Litz
RIA
+44 7884 735627
Nick Stone
CVMD
+44 7717 618834
Craig Marks
Finance
+44 7881 615764
Christer Gruvris
Consensus Forecasts
+44 7827 836825
US


Lindsey Trickett
 Oncology, ING
+1 240 543 7970
Mitch Chan
 Oncology
+1 240 477 3771
Dial / Toll-Free

+1 866 381 7277
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, 
ING - Infection, Neuroscience and Gastrointestinal
03 May 2016
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCBIGDUBBGBGLD